title: Repositioning of dexamethasone intravitreal implant (Ozurdex) migrated into the anterior chamber.
abstract: Ozurdex (Allergan Inc., Irvine, CA, USA) is a biodegradable implant of dexamethasone (0.7 mg) injected into the vitreous cavity to treat macular oedema. We report a case of migration of Ozurdex into the anterior chamber in a patient who had a previous iris-claw lens implantation. Surgical removal of the implant was avoided due to the absence of anterior complications and the loss of effectiveness of the drug delivery system. Repositioning of the implant to the posterior segment is described. This case illustrates the efficacy of this technique in cases of migration into the anterior chamber in eyes without corneal decompensation.
authors: Department of Ophthalmology, Institut Condal d'Oftalmologia, C/Aragó 469 4º 5º, 08013 Barcelona, Spain. 34128jvs@gmail.com
authors: José I
authors: JI
authors: Vela
authors: Jaume
authors: J
authors: Crespí
authors: David
authors: D
authors: Andreu
mesh_terms: D000368:Aged; D000867:Anterior Chamber; D003907:Dexamethasone / Q000494:pharmacology*; D004343:Drug Implants; D005260:Female; D005548:Foreign-Body Migration / Q000175:diagnosis / Q000601:surgery*; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy*; D012086:Reoperation / Q000379:methods; D014822:Vitreous Body
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone